Clinical trials: Renal Transplant Patient
Delayed Graft Function
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not…
- Trial name
- NCT01794663
- Testing
- OPN-305
- Where
- 50 sites in United States, Austria and 9 more
- Volunteers
- 252 people
- Sponsor
- Opsona Therapeutics Ltd.
High Blood Pressure
ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)
To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional therapy) will reduce the number of RT patients who experience histological lesions of chronic allograft nephropathy
- Trial name
- NCT00140907
- Testing
- losartan potassium
- Volunteers
- 367 people
- Sponsor
- Organon and Co
Kidney Transplant; Complications, Immunosuppression
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
Solid organ transplantation is the treatment of choice for patients suffering from end-stage organ disease, including for chronic kidney failure.
- Conditions
- Kidney Transplant; Complications, Immunosuppression, Transplant Failure
- Trial name
- NCT04360031
- Testing
- Tacrolimus
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Severe Obesity, Renal Failure
Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure
Gastric Bypass followed by renal transplantation is superior to medical management followed by renal transplant for patients with severe obesity and renal failure.
- Trial name
- NCT02128802
- Testing
- Gastric Bypass, Weight Loss Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Lung Transplant; Complications
Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients
Lung transplantation is a life-saving option in patients with end-stage lung disease. The introduction of calcineurin inhibitors has significantly improved long-term outcome in lung transplantation.
- Trial name
- REVOLUTION (NCT05001074)
- Testing
- Extended release tacrolimus, Immediate release tacrolimus
- Where
- Netherlands
- Volunteers
- 145 people
- Sponsor
- Heleen Grootjans
Kidney Transplant Rejection
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free…
- Trial name
- NCT07415876
- Testing
- Retrospective Cohort Enrollment, Prospective Cohort Enrollment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Kidney Transplant Recipients
Measuring and Improving Medication Adherence in Kidney Transplant Patients
Nonadherence to medication is a major obstacle to successful treatment of renal transplant patients. This study has two primary aims.
- Trial name
- NCT02639949
- Testing
- Cognitive-behavioral adherence promotion program, Standard Care
- Volunteers
- 45 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Renal Transplantation
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
This is a retrospective analysis of two different cohorts of patients that has undergone renal transplantation. This is a matched pair analysis of 100 patients treated with generic tacrolimus that will be compared with 100…
- Trial name
- GenTac (NCT02587052)
- Testing
- Generic tacrolimus, Prograf
- Where
- Sweden
- Volunteers
- 186 people
- Sponsor
- Vastra Gotaland Region
Heart Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant.
- Trial name
- NCT02091414
- Testing
- mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Dialysis
The KidneyCARE (Community Access to Research Equity) Study
For chronic kidney disease (CKD), there is a lack of unique and powerful platform for patient engagement, research studies and public health advocacy work.
- Conditions
- Chronic Kidney Disease, Dialysis, Kidney Transplant
- Trial name
- NCT05497518
- Testing
- Observational study - registry
- Where
- United States
- Volunteers
- 50,000 people
- Sponsor
- Tufts Medical Center
Kidney Transplantation
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
- Trial name
- NCT00098241
- Testing
- Certican
- Where
- 2 sites in United States, Belgium
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
End Stage Kidney Disease, Immunological Tolerance
Immunological Tolerance in Patients With Mismatched Kidney Transplants
This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05806749
- Testing
- Donor CD34+, CD3+. and belumosudil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Function of Renal Transplant
Protocol Calcineurin Inhibitor (CNI) Weaning
The main objective of this study is to demonstrate the benefit of the withdrawal of Tacrolimus (Prograf®) on renal function in patients one year after the end of the weaning period.
- Trial name
- NCT01292525
- Testing
- Tacrolimus
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Nantes University Hospital
Kidney Failure
Immune Monitoring in Sensitized Patients at Risk of Rejection
The purpose of this study is to test the effect of anti-rejection medications on your immune system
- Trial name
- PRISM (NCT03794817)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, San Francisco
Kidney Failure, Chronic, Kidney Transplantation
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization
- Trial name
- HIPER-RESET (NCT07607197)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Kidney Transplant
Use of Predigraft in Kidney Transplant Patients
Kidney transplantation is the treatment of choice for end-stage renal disease in terms of morbidity, mortality, and cost-benefit ratio. Graft loss is mainly related to the occurrence of rejection.
- Trial name
- PREDIGRAFT2 (NCT04969757)
- Testing
- Predigraft group
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Bypass Surgery, Coronary Heart Disease
Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA
The purpose of this study is to assess the effects of nesiritide compared to placebo when given with standard of care therapies, on kidney function, heart function and the need of other treatments in heart failure patients…
- Conditions
- Coronary Artery Bypass Surgery, Coronary Heart Disease, Coronary Artery Bypass Grafting, Cardiopulmonary Bypass
- Trial name
- NCT00653042
- Testing
- Nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
Multiple Myeloma
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
This is a single-arm, open-label phase II study with a safety lead-in phase.
- Trial name
- VICD (NCT04240054)
- Testing
- Bortezomib, Isatuximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Medical College of Wisconsin